Itaconate and itaconate analogues capable of inhibiting succinate dehydrogenase can be used to treat or prevent tissue fibrosis.

Itaconate and itaconate analogues capable of inhibiting succinate dehydrogenase can be used to treat or prevent tissue fibrosis.
Dr Britany Clarke is an Industry Partnership and Commercialisation Officer in the Faculty of Medicine at Imperial College London.
A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics
Dr Amritha Nair is an Industry Partnerships and Commercialisation Senior Executive in the Faculty of Medicine at Imperial College London. Amritha works across the entire innovation lifecycle from assessment, protection, and management of Intellectual property;...
Imperial.Tech.Pitch: Affordable technologies for an ageing society centred on the premise that within 20 years, there will be 25% fewer taxpayers to pensioners in the UK than in 2020.
Learn about our programme of events and sign up to be alerted for future events
Rachel is Industry Partnerships and Commercialisation Officer for the Faculty of Medicine.
Imperial will benefit from continued support for translational biomedical research under a unique technology transfer model.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.